Aspirin 50mg vs 100mg Combined With P2Y12 Inhibitor After PCI
NCT07846462
Summary
This is a randomized, open-label, active-controlled, non-inferiority clinical trial (the ASPIRE-LD trial) conducted in China. It aims to compare the efficacy and safety of low-dose aspirin (50 mg once daily) versus standard-dose aspirin (100 mg once daily), both in combination with a P2Y12 inhibitor, in patients who have successfully undergone percutaneous coronary intervention (PCI) and plan to receive at least 12 months of dual antiplatelet therapy (DAPT). A total of 2640 eligible patients will be randomly assigned in a 1:1 ratio to receive either 50 mg or 100 mg of enteric-coated aspirin daily, plus a P2Y12 inhibitor (ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily, prescribed according to routine clinical practice). All participants will be followed for 12 months after randomization. The primary goal is to verify that 50 mg aspirin is non-inferior to the 100 mg standard dose in preventing major adverse cardiac and cerebrovascular events (MACCE: cardiovascular death, non-fatal myocardial infarction, definite/probable stent thrombosis, and ischemic stroke) at 12 months post-PCI. If non-inferiority is confirmed, the study will further test whether 50 mg aspirin reduces clinically relevant bleeding events (BARC type 2, 3, or 5) better than the standard dose. The study is sponsored by the First Hospital of Jilin University and will be carried out in 10-15 tertiary hospitals across China. Its findings will provide evidence for optimizing aspirin dosing in post-PCI DAPT.
Eligibility
Inclusion Criteria: * Aged 18 to 85 years at the time of screening * Diagnosed with acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) * Has undergone successful percutaneous coronary intervention (PCI) with stent implantation * Planned to receive at least 12 months of dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor after PCI * Able to provide written informed consent and comply with study follow-up requirements Exclusion Criteria: * Known hypersensitivity or contraindication to aspirin, P2Y12 inhibitors, or related excipients * High bleeding risk: history of intracranial hemorrhage, gastrointestinal bleeding within 6 months, active bleeding diathesis, or coagulopathy * Severe hepatic dysfunction (Child-Pugh class C) or severe renal impairment (eGFR \< 30 mL/min/1.73 m²) * Ischemic or hemorrhagic stroke within 3 months before enrollment * Pregnant or lactating women; women of childbearing potential unwilling to use effective contraception * Life expectancy \< 12 months due to other severe comorbidities such as advanced malignancy * Participation in another interventional clinical trial within 30 days before screening * Any other condition judged by the investigator to make the patient unsuitable for the study
Conditions5
Interventions2
Related trials
- ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography — Jung-min Ahn
- Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention — Peking Union Medical College Hospital
- AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE — University Hospital, Bordeaux
- Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma — Chen Lijuan
- COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes — Montreal Heart Institute
- Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes — Seoul National University Bundang Hospital
- Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI — Medical University of Gdansk
- Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization — Takeshi Morimoto
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07846462